Cargando…
SPRED1 deletion confers resistance to MAPK inhibition in melanoma
Functional evaluation of genetic lesions can discover a role in cancer initiation and progression and help develop novel therapeutic strategies. We previously identified the negative MAPK regulator SPRED1 as a novel tumor suppressor in KIT-driven melanoma. Here, we show that SPRED1 is also frequentl...
Autores principales: | Ablain, Julien, Liu, Sixue, Moriceau, Gatien, Lo, Roger S., Zon, Leonard I. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Rockefeller University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7927430/ https://www.ncbi.nlm.nih.gov/pubmed/33306107 http://dx.doi.org/10.1084/jem.20201097 |
Ejemplares similares
-
Spred-2 Suppresses Aorta-Gonad-Mesonephros Hematopoiesis by Inhibiting MAP Kinase Activation
por: Nobuhisa, Ikuo, et al.
Publicado: (2004) -
Blocking Genomic Instability Prevents Acquired Resistance to MAPK Inhibitor Therapy in Melanoma
por: Dharanipragada, Prashanthi, et al.
Publicado: (2023) -
Enhancing PD-L1 Degradation by ITCH during MAPK Inhibitor Therapy Suppresses Acquired Resistance
por: Yang, Zhentao, et al.
Publicado: (2022) -
Uncoupling RARA transcriptional activation and degradation clarifies the bases for APL response to therapies
por: Ablain, Julien, et al.
Publicado: (2013) -
The BRAF–MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells
por: Sumimoto, Hidetoshi, et al.
Publicado: (2006)